Article
In the following video, Mark Forchette, president and CEO of OptiMedica, discusses how the FDA approval of the Catalys femtosecond laser for creating single-plane and multi-plane arc incisions during cataract surgery, and its subsequent market launch, means to the company.
In the video, Mark Forchette, president and CEO of OptiMedica, discusses how the FDA approval of the Catalys femtosecond laser for creating single-plane and multi-plane arc incisions during cataract surgery, and its subsequent market launch, means to the company. The discussion continues with Robert P. Rivera, MD, director of clinical research, intraocular lens, and refractive surgery at Hoopes Vision, Draper, UT, offering a clinical perspective of femtosecond laser platforms.
To get more videos from Ophthalmology Times, subscribe to our YouTube channel.